Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 22 of 22 publications.
Skip to main content
Talbird SE, Mauskopf J, Smets E, Brogan AJ. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial. Pharmacoeconomics. 2010 Dec 23;28(Suppl 1):129-46.
Chung RT, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, Di Bisceglie AM. Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. Hepatology. 2010 Dec 1;52(6):1906-14. doi: 10.1002/hep.23947
Mladsi DM, Redekop K, Goettsch A, Earnshaw SR. Challenges and insights in establishing and communicating the economic value of companion diagnostics. Presented at the 2010 ISPOR 13th Annual European Congress; November 2010. Prague, Czech Republic.
Karve S, Misurski D, Miller JM, Davis KL. Long-term economic and clinical burden of complicated invasive meningococcal disease: evidence from a United States managed care population. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. [abstract] Value Health. 2010 Nov; 13(7):A432.
Mladsi D, Earnshaw S, Ronquest NA, Keith M. The threshold pricing model: not just another cost-effectiveness model. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. Prague, Czech Republic. [abstract] Value Health. 2010 Nov; 13(7):A332.
Davis AE, Ladner D, Friedewald J. Analysis of kidney transplant center locations in the United States. Poster presented at the American Society of Nephrologists; November 2010. Previously presented at the American Transplant Congress.
Davis AE, Mehrotra S, Daskin MS. Distribution robust newsvendor models for shift nurse demand estimation. Poster presented at the Annual Meeting of the Institute for Operations Research and Management Science; November 2010.
Pockros PJ, Hamzeh FM, Martin P, Lentz E, Zhou X, Govindarajan S, Lok AS. Histologic outcomes in hepatitis C–infected patients with varying degrees of virologic response to interferon-based treatments. Hepatology. 2010 Oct 1;52(4):1193-200.
Davis KL, Misurski DA, Miller JD, Karve SJ. Impact of invasive meningococcal disease-related complications on health care utilization and costs. Poster presented at the 48th Annual Meeting of the Infectious Diseases Society of America; October 2010.
Karve SJ, Misurski DA, Herrera-Taracena G, Davis KL. Health care utilization and costs associated with influenza-related complications: findings from a large United States managed care population. Poster presented at the 48th Annual Meeting of the Infectious Diseases Society of America; October 2010.
Meyers JL, Davis KL, Yu Y. ACE inhibitor treatment adjustment and subsequent health care costs among managed care enrollees with hypertension. Poster presented at the Education Conference of the Academy of Managed Care Pharmacies; October 2010.
Pattanayak SK, Poulos C, Yang JC, Patil S. How valuable are environmental health interventions? Evaluation of water and sanitation programmes in India. Bull World Health Organ. 2010 Jul 1;88(7):535-42.
Knoll S, Jochum D, Talbird S. Comparative cost benefit analysis of two new Pneumococcal Conjugate Vaccines (PHiD-CV and PCV-13). Klin Padiatr. 2010 Jun 1;222(Suppl 1):S51-2.
Talbird SE, Bell K, Graham JB, Deal L, Mauskopf J. Cost-effectiveness analysis for treatment of symptomatic uterine fibroids among premenopausal women seeking to retain uterus. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A183.
Chung RT, Bisceglie A, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, Hamzeh FM. Association of host pharmacodynamic effects and virologic response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis c. Poster presented at the 2010 Digestive Disease Week; May 1, 2010. New Orleans, LA. [abstract] Gastroenterology. 2010 May; 138(5_suppl_1):S-841.
Ervin CM, Fehnel S, Carson R, Kurtz C, Shiff S, Johnston J. Selecting chronic constipation (CC) clinical trial endpoints: incorporating the patient's voice. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 28, 2010. [abstract] Value Health. 2010 May; 13(3):A74.
Graham C, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating a cost-effectiveness analysis comparing olanzapine with ziprasidone in the treatment of schizophrenia. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May 1; 13(3):A113.
Davis AE, Ladner D, Friedewald J. Analysis of kidney transplant center locations in the United States. Poster presented at the 2010 American Transplant Congress; May 2010.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Brodtkorb T, Zetterström O, Tinghög G. Cost-effectiveness of clean air administered to the breathing zone in allergic asthma. Clin Respir J. 2010;4(2):104-10.
Zaniolo O, Wolowacz SE, Pradelli L. Modello di costo/efficacia di dabigatran nella profilassi del tromboembolismo venoso in chirurgia ortopedica maggiore: adattamento per l'Italia. Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2010;11(2):91-101.
Zaniolo O, Wolowacz SE, Pradelli L. Economic performance of dabigatran etexilate for primary VTE prevention following total hip and knee replacement surgery in Italy [Modello di costo/efficacia di dabigatran nella profilassi del tromboembolismo venoso in chirurgia ortopedica maggiore: adattamento per l'Italia]. Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2010;11(2):91-101.